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Abstract
Background: DNA deletion and duplication were determined as the major mutation underlying
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).
Method: Applying multiplex ligation-dependent probe amplification (MLPA), we have analyzed 179
unrelated DMD/BMD subjects from northern China.
Results:  Seventy-three percent of the subjects were found having a deletion (66.25%) or
duplication (6.25%). Exons 51–52 were detected as the most common fragment deleted in single-
exon deletion, and the region of exons 45–50 was the most common exons deleted in multi-exon
deletions. About 90% of DMD/BMD cases carry a small size deletion that involves 10 exons or less,
26.67% of which carry a single-exon deletion. Most of the smaller deletions resulted in an out-of-
frame mutation. The most common exons deleted were determined to be between exon 48 and
exon 52, with exon 50 was the model allele. Verifying single-exon deletion, one sample with a
deletion of exon 53 that was initially observed from MLPA showed that there was a single base
deletion that abolished the ligation site in MLPA. Confirmation of single-exon deletion is
recommended to exclude single base deletion or mutation at the MLPA ligation site.
Conclusion: The frequency of deletion and duplication in northern China is similar to global ethnic
populations.
Background
Duchenne muscular dystrophy (DMD) and its less severe
allelic form Becker muscular dystrophy (BMD) are com-
mon X-linked recessive neuromuscular degeneration dis-
eases [1,2]. The incidence of DMD is 1/3500 and BMD is
1/18,000 in male living births, respectively [3,4]. They
both are caused by genetic defects of the dystrophin gene,
which is located at Xq21.2, spanning 2.4 Mb [5,6]. The
dystrophin gene consists of 79 exons and encodes a 14.6
kb mRNA, which is expressed in skeleton, muscles and
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brain [7]. Deletions, duplications and point mutations
have been reported in most exons of this gene. There were
two deletion hot-spot regions, one is located at the 5'
exons 2–20 and the other, located between exons 44–53
[8,9]. Mutations affecting open-reading frame (ORF), due
to a frameshift, may result in an aberrantly spliced mRNA
and generate a truncated, nonfunctional dystrophin pro-
tein that usually gives rise to the DMD/BMD phenotypes.
However, mutations not affecting the ORF may produce a
semi-functional dystrophin protein and usually correlate
with mild phenotypes [10]. Levels of dystrophin protein
in DMD are very low (<3% of normal) or absent, how-
ever, BMD patients have 10–40% of the normal amount
of dystrophin with an abnormal molecular weight
[11,12]. About 65% of cases are caused by deletion
[8,9,13], approximately 5% by duplication [9,14] and the
remaining is point mutation of the dystrophin gene [15].
Due to no effective treatment available for DMD/BMD,
presently an accurate genetic diagnosis may offer prenatal
diagnosis for the familial DMD/BMD although about
one-third of mutations are de novo [16]. Although the fre-
quency of complex rearrangement was reported as high as
4% [17], usually complex rearrangement is considered as
a rare condition [18-20] that includes double deletion
[17] and non-contiguous duplications [21-23].
In this study, we have analyzed a subset of DMD/BMD
patients from Northern China.
Methods
Subjects
A total number of 179 unrelated patients in northern
China were studied. There were 160 affected male
probands and 19 females who had an affected son clini-
cally diagnosed as DMD/BMD. This study was approved
by the Institutional Ethic Committee and informed con-
sent was obtained from all participants.
Multiplex ligation-dependent probe amplification (MLPA)
MLPA is a reliable technology for quantitative analysis of
the copy number in clinical diagnosis of genetic diseases
[24]. It has the capability of detecting either large or small
genomic deletions or duplications [20,25]. An MLPA kit
with probes of P034 and P035 for detecting deletion and/
or duplication of the DMD gene was purchased commer-
cially from MRC Holland (Amsterdam, Netherlands).
Procedures were following the manufacturer's instruction.
Ligation and amplification were carried out with an ABI
9800 Thermal Cycler. The PCR conditions were 35 cycles
at 95°C for 30s, 60°C for 30s, and 72°C for 60s; followed
by a final incubation at 72°C for 20 min.
The PCR products were separated by capillary electro-
phoresis in an ABI 310 Genetic Analyzer with Genescan
3.7 (Applied Biosystems, Foster City, California) software.
The raw data was analyzed by Genescan Analysis 3.7 soft-
ware. The peaks obtained after the analysis of the row data
(Fig. 1A) could be distinguished and assigned to specific
exons on the basis of their different lengths representing
the variability of their stuffer sequences. Peak area of raw
data can be also exported into a Microsoft excel spread-
sheet program (Fig. 1B), which normalizes each peak to
that of a known normal control (Fig. 1, 1). Peaks derived
from DMD/BMD patients (Fig. 1, 2–5) that vary more
than 20% from the normal should be flagged for review.
If a deletion of a single exon was observed, conventional
PCR and DNA sequencing analysis of the specific region
embedding the deleted exon was performed to verify the
deletion [20,21].
Results
Detection of DMD gene deletion with MLPA
Among 160 male probands, 106 were found to have dele-
tions, accounting for 66.25% of male patients analyzed.
Among 19 females who had an affected boy but without
previous genetic confirmation, 14 with exonic deletion
were detected, which brought the deletion rate to 67.04%
(120/179). Duplication mutation was identified from 10
(16.95%) of the remaining 59 people (54 male patients
and 5 female carriers) who had no deletion identified.
Totally, 130 of 179 (72.63%) were found to have muta-
tions (Table 1).
Detection of single-exon deletion may result from 1-bp 
deletion
When a single-exon deletion was observed, DNA sequenc-
ing would be applied for verification. Among 32 DNA
samples with single-exon deletion, DNA sequencing
observed a 1-bp deletion (NM_004006.1, c.8027delG) in
one case that had a deletion of exon 53 detected by initial
MLPA. This 1-bp deletion (Fig. 2) was located precisely at
the ligation site and destroyed the ligation that resulted in
failure of amplification of the probes in MLPA.
Deletion of small fragment is predominant in DMD gene
Analyses of 106 males and 14 females (Table 1) showed
that 26.67% (29 males and 3 females) of deletions
involved a single-exon; 14.17% (15 males and 2 females)
exhibited 3-exon deletion; 10.83% (12 males and 1
female) had 5- or 6-exon deletion, 8.33% (10 males) had
2-exon deletion, 7.50% (5 males and 4 females) showed
4-exon deletion, 5.0% (6 males) had 10-exon deletion,
4.17% (5 males) had 8-exon deletion, and 1.67% (2
males) had 7-exon deletion. Our results showed that dele-
tion of six exons and smaller accounts for 77.5% (93/
120). To combine all deletions smaller than 10 exons, this
group deletion may account for 88.33% (106/120) of
patients and carriers.Behavioral and Brain Functions 2008, 4:20 http://www.behavioralandbrainfunctions.com/content/4/1/20
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MLPA results were selected from a normal control (1), a multi-exon deletion (2), a multi-exon duplication (3), a single-exon  duplication (4), and a single-exon deletion (5) Figure 1
MLPA results were selected from a normal control (1), a multi-exon deletion (2), a multi-exon duplication (3), a single-exon 
duplication (4), and a single-exon deletion (5). Raw data are shown on the left panels (A). Each peak represents one exon of the 
dystrophin gene. Arrow(s) indicate missing signals representing deleted exon(s). The corresponding relative peak area (RPA) 
ratios, after statistical analysis, are shown on the right panels (B), in which each bar represents the RPA ratio compared to the 
mean of two male control samples.
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Table 1: Mutation Detected in Dystrophin Gene
Size of deletion or 
duplication
Independent cases 
(N = 120)
Distribution (%) Exon deleted or 
duplicated
Fragment deleted or 
duplicated ∆
IF/OF OF Minimal deletion/
duplication (bp)
1 exon (n = 32) 1 0.83 DelEX07 c.531-?*_649+?*del OF 118
1 0.83 DelEX17 c.1993-?_2168+?del OF 175
2 1.67 DelEX18 c.2169-?_2292+?del OF 123
1 0.83 DelEX19 c.2293-?_2380+?del OF ?
1 0.83 DelEX35 c.4846-?_5025+?del IF 179
2 1.67 DelEX43 c.6118-?_6290+?del OF 172
1 0.83 DelEX44 c.6291-?_6438+?del OF 147
5 4.17 DelEX45 c.6439-?_6614+?del OF 175
2 1.67 DelEX50 c.7201-?_7309+?del OF 108
6 5 DelEX51 c.7310-?_7542+?del OF 232
6 5 DelEX52 c.7543-?_7660+?del OF 117
2 1.67 DelEX53* c.7661-?_7872+?del OF 211
2 1.67 DelEX54 c.7873-?_8027+?del OF 154
2 exons (n = 10) 1 0.83 DelEX10-11 c.961-?_1331+?del OF 1020
1 0.83 DelEX42-43 c.5923-?_6290+?del OF 22747
2 1.67 DelEX46-47 c.6615-?_6912+?del OF 2631
4 3.33 DelEX48-49 c.6913-?_7200+?del IF 38655
2 1.67 DelEX49-50 c.7099-?_7309+?del OF 104
3 exons (n = 17) 1 0.83 DelEX03-05 c.94-?_357+?del IF 26525
2 0.83 DelEX46-48 c.6615-?_7098+?del OF 57036
6 5 DelEX48-50 c.6913-?_7309+?del OF 55398
2 1.67 DelEX50-52 c.7201-?_7660+?del OF 90452
3 2.5 DelEX51-53 c.7310-?_7872+?del OF 94817
1 0.83 DelEX52-54 c.7543-?_8027+?del OF 71758
2 1.67 DelEX53-55 c.7661-?_8217+?del OF 51913
4 exons (n = 9) 1 0.83 DelEX10-13 c.961-?_1602+?del IF 49395
1 0.83 DelEX22-25 c.2804-?_3432+?del OF 8870
3 2.5 DelEX45-48 c.6439-?_7098+?del IF 93323
1 0.83 DelEX46-49 c.6615-?_7200+?del OF 95509
2 1.67 DelEX49-52 c.7099-?_7660+?del OF 107011
1 0.83 DelEX50-53 c.7201-?_7872+?del IF 140708
5 exons (n = 12) 2 1.67 DelEX03-07 c.94-?_649+?del OF 40327
1 0.83 DelEX13-17 c.1483-?_2168+?del OF 50717
1 0.83 DelEX17-21 c.1993-?_2803+?del OF 60415
3 2.5 DelEX46-50 c.6615-?_7309+?del OF 102252
3 2.5 DelEX48-52 c.6913-?_7660+?del OF 145742
1 0.83 DelEX50-54 c.7201-?_8027+?del OF 162093
1 0.83 DelEX51-55 c.7310-?_8217+?del OF 146519
6 exons (n = 13) 7 5.83 DelEX45-50 c.6439-?_7309+?del OF 148539
1 0.83 DelEX46-51 c.6615-?_7542+?del OF 158627
1 0.83 DelEX47-52 c.6763-?_7660+?del OF 200114
4 3.33 DelEX49-54 c.7099-?_8027+?del OF 178832
7 exons (n = 2) 2 1.67 DelEX46-52 c.6615-?_7660+?del OF 202596
8 exons (n = 5) 4 3.33 DelEX45-52 c.6439-?_7660+?del OF 238883
1 0.83 DelEX46-53 c.6615-?_7872+?del OF 252852
10 exons (n = 6) 3 2.5 DelEX45-54 c.6439-?_8027+?del OF 310524
3 2.5 DelEX46-55 c.6615-?_8217+?del OF 304554
11 exons (n = 3) 3 2.5 DelEX45-55 c.6439-?_8217+?del IF 340841
12 exons (n = 1) 1 0.83 DelEX31-42 c.4234-?_6117+?del IF 80099
16 exons (n = 1) 1 0.83 DelEX8-23 c.650-?_3162+?del OF 230795
20 exons (n = 1) 1 0.83 DelEX11-30 c.1150-?_4233+?del IF 232561
27 exons (n = 1) 1 0.83 DelEX3-29 c.832-?_3162+?del IF 411579
30 exons (n = 1) 1 0.83 DelEX10-39 c.961-?_5586+?del IF 299209
35 exons (n = 1) 1 0.83 DelEX10-44 c.961-?_6438+?del IF 428236
37 exons (n = 1) 1 0.83 DelEx8-44 c.650-?_6438+?del OF 482377
39 exons (n = 1) 1 0.83 DelEX3-41 c.94-?_5922+?del IF 507720
41 exons (n = 1) 1 0.83 DelEX3-43 c.94-?_6290+?del OF 562291
42 exons (n = 2) 2 1.67 DelEX3-44 c.94-?_6438+?del IF 632904
Dup1 exons 1 0.83 DupEX45 c.6439?_6614+?dup OF 175
Dup3 exons 1 0.83 DupEX48-50 c.6913?_7309+?dup OF 55398
Dup5 exons 1 0.83 DupEX3-7 c.94-?_649+?dup OF 40327
Dup11 exons 1 0.83 DupEX64-74 ? OF 53678
Dup14 exons 1 0.83 DupEX3-16 c.94-?_1992+?dup IF 284118
Dup21 exons 1 0.83 DupEX54-74 c.7873-?_10553+?dup OF 488701
Dup27 exons 1 0.83 DupEX8-34 c.650-?_4845+?dup OF 318783
Dup29 exons 1 0.83 DupEX13-41 c.1483-?_5922+?dup IF 253776
Dup37 exons 1 0.83 DupEX8-44 c.650-?_6438+?dup OF 482377
Dup41 exons 1 0.83 DupEX3-43 c.94-?_6290+?dup OF 562291
∆: data were obtained through online search from [26].
?: the actual breakpoint is unknown.
*: DNA sequencing analysis determined that this single exon deletion is due to a single base pair deletion (Fig. 2).
IF/OF: in frame or out-of-frame.Behavioral and Brain Functions 2008, 4:20 http://www.behavioralandbrainfunctions.com/content/4/1/20
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Duplication detected in this study involved a large 
fragment
Ten patients with duplication were identified. Most of the
duplications involved large fragments, among which six
spun 11 to 41 exons. Eight duplications involved previ-
ously identified 3' region. A large 21-exon duplication was
beyond the 3' hot-spot region that has reached exon 74.
Only three duplications in this study were found to
involve small fragment.
Exons 48–52 were the most common region deleted
Analysis of the single-exon deletion among the 32 (29
males, three females) patients showed that both exons 51
and 52 were the most common exons deleted, accounting
for 18.75% (6/32) respectively, followed by exon 45
(15.63%). Single-exon deletion was not found in exons
1–6, 8–16, 20–34, 36–42, 46–49, and 55–79. Among the
88 cases with multiple exons (multi-exon), deletion of six
exons in 45–50 were the most common (7.95%), fol-
lowed by deletion of three exons in 48–50 (6.82%), and
then two exons in 48–49 and eight exons in 45–52. When
the frequency of deletion for individual exon of dys-
trophin gene was considered, the most common deleted
was exon 50, followed by exon 49 (6.54%), then exon 48
(6.01%), and exons 51 (5.10%). Deletion of exons from
45 to 54 accounts for 50.16%. No deletion was found in
either 5' end exons 1–2 or 3' end exons 56–79 (Fig. 3).
Out-of-frame mutation is predominant in DMD/BMD
It has been considered that clinical severity is correlated to
in frame or out-of-frame deletion of the dystrophine gene
[26]. An interesting result we noticed from this study was
that for smaller deletions, they usually resulted in out-of-
frame mutations. Among 106 small deletion that
involved ten or less exons, there were only 11 cases that
carried in-frame but 89.62% had out-of-frame. However,
among 14 larger deletions, there were 11 (78.57%) cases
had in-frame mutations. This data suggested that out-of-
frame mutations in smaller deletion cases account for the
majority of DMD mutations, which likely resulted in a
severe phenotype. Among five larger duplications, there
was only one that was an in-frame mutation while the
others were out-of-frame mutations, and there was no in-
frame mutation in two small duplications. Overall,
81.53% of duplications were out-of-frame. Correlating
each DNA sample with its clinical phenotypes would be
idea for drawing a clearer picture. A regret of this study,
unfortunately, was that the clinical information had been
incomplete which made us unable to perform an analysis
on genotype-phenotype correlation. We encourage to per-
form a genotype-phenotype study with a larger cohort in
order to draw a better clue.
Discussion
Several studies have shown that MLPA were useful in
detecting mutation quantitatively, not only for deletions
but also duplications and female carriers in the DMD gene
[20,25,27-29]. We applied MLPA in a subset of DMD/
BMD patients in northern China. Our results indicated
that 66.25% (106/160) of our patients carry deletion and
6.25% (10/160) patients had a duplication, which
brought the sensitivity of detecting DNA rearrangement
up to 72.5%. In addition, MLPA may present higher sen-
sitivity. In this study, three patients who had negative
results in their previous DNA testing by multiplex PCR
(data not shown) were identified. Furthermore, an advan-
tage of employing MLPA in clinical genetic testing is that
it is capable of identifying female carriers, as we have dem-
onstrated among 14 out of 19 females who came to our
prenatal clinics. Certainly, MLPA should be considered as
the initial test for the clinically suspected DMD/BMD
patients as well as for women who have a DMD/BMD
family history, as suggested previously [29], to provide
both confirmation of genetic defects on DMD gene and
better genetic counseling.
Exons 2–20 and exons 44–53 had been previously
reported as the two-hotspot regions [8,9]. In this study, we
have analyzed the distribution of individual exons regard-
ing their frequency of deletion or duplication (Fig. 4). Our
data indicates that the deletion occurs at exons 45 to 55
accounting for 47.67%, followed by exons 21–44
(26.67%) and exons 1–20 (23.66%). If both deletions
and duplications are counted together, the most frequent
mutant region occurs within exons 45–55 (41.06%) in
the DMD gene, followed by exons 21–44 (30.43%), exons
1–20 (25.32%) and exons 56–79 (3.19%). We found the
most common region in our study is the exons 45–55,
Sequencing analyses to validate single-exon deletion Figure 2
Sequencing analyses to validate single-exon deletion. One 
sample detected as a single-exon deletion of exon 53 was 
found that the deletion was resulted from a single base pair 
deletion, rather than an entire exon deletion. This single base 
pair deletion abolished the ligation of the probe.
                
G A G C A GG T C T T A G (Normal)Behavioral and Brain Functions 2008, 4:20 http://www.behavioralandbrainfunctions.com/content/4/1/20
Page 6 of 9
(page number not for citation purposes)
and the least common region is the exons 56–79. These
data are in agreement with other global populations [26].
We have noticed that the frequency of duplication is more
than 20% and it appears there is no model peak of dele-
tion in Taiwan (Fig. 4) [21,22,27,30-32]. As well, the dele-
tion rate in Hong Kong [31] showed difference from the
northern Chinese. We hypothesize that the frequency of
deletion is different in variant regions of China, and we
propose that further investigation with molecular screen-
ing of deletion (and duplication) should be pursued
among newborns in China. The pattern of duplication did
not show significant difference among the global variant
populations (Fig. 4).
The structure of introns of dystrophin gene determines the
breakpoint that is responsible for the deletion [33]. There
were many repeated sequences in introns of dystrophin
gene which resulted in many breakpoints. For example, in
intron 44 there were 13 breakpoints resulted in the hot-
spot deletion region [34]. The repeated sequences
included direct repeated sequence, inverted repeat
sequence and homology sequence. It was reported that 22
repeated sequences had been found in intron 51 and
intron 52, which was a possible reason for the high fre-
quency of single-exon deletion at exon 51 [35]. We believe
this might be the same case for the most common dele-
tion at exon 50.
Recently, White et al [25] reported that as high as 87% of
duplications can be detected among three subsets of
selected DMD/BMD cases, among which no deletion or
point mutation had been found. In this study, duplication
was only detected in 18.51% of the cases where no dele-
tion could be detected. This lower rate possibly resulted
from either our small size of samples or a high rate of
point mutation, which should be further investigated. To
combine the rates of duplication with deletion, we esti-
mate that a point mutation might account for 20–28% of
our cases. In addition, the duplications in our cases
mainly involved a larger fragment; however, among 118
cases of the reported duplications [25], there were only 12
cases where the duplication was more than 20 exons.
In summary, we have applied MLPA to detect DNA rear-
rangements of deletions and duplications among DMD/
BMD male patients and female potential carriers. We have
determined that deletions and duplications were 72.5%
of our samples. We observed that the majority of deletions
was small in size that the number of deleted exons was
less than 10 but duplications usually involved larger sizes.
Finally, we determined that the most common region of
DMD gene rearrangement is between exons 45 and 55
and the 5' hotspot region was not a hotspot region in our
study.
Conclusion
MLPA is an effective and cost effective technique to detect
a large number of samples. In our study, we found the fre-
quency of deletion/duplication of DMD in the northern
China is similar to other population. We recommend that
MLPA should be applied as the first line for clinical molec-
ular testing for DMD/BMD.
Frequency of DMD gene mutations showed that deletion of exon 50 is the most common in the DMD gene deletions, which  brought the exon 50 as the model allele in the DMD gene deletion Figure 3
Frequency of DMD gene mutations showed that deletion of exon 50 is the most common in the DMD gene deletions, which 
brought the exon 50 as the model allele in the DMD gene deletion. There is no specific peak showing a model duplicated exon.
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Comparison of exon deletion (A) and duplication (B) among global populations Figure 4
Comparison of exon deletion (A) and duplication (B) among global populations. All these data showed that exons 45–55 are 
the most frequent deletion region of DMD gene. Deletion and duplication were not common in region of exons 56–79, 
although the data may derive from variant methodology (MLPA for Hong Kong, Taiwan, Denmark, Australia, and the current 
study; quantitative multiplex PCR for Canada; and multiplex PCR and Southern blotting for Japan and USA).
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